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the National Health Care system perspective. Results: Preoperative characteris-
tics and risk scores of the 2 groups were comparable. Hospital mortality was 3.7% 
in Sutured and 2.4% in Sutureless (p= 0.65). Aortic cross-clamp, cardiopulmonary 
bypass time and operation time were 20%, 23% and 16% shorter in Sutureless (each 
one p< 0.001).Sutureless required less blood transfusion (1.2±1.3 vs 2.5±3.7 units, 
p= 0.005) with a similar incidence of postoperative bleeding (2 patients vs 5, p= 0.221). 
Sutureless had a shorter intensive care unit stay (2.0±1.72vs 2.8±1.3 days, p< 0.001), 
a shorter hospital stay (11.4±3.9 vs 17.3±13.7 days, p< 0.001) and a shorter intuba-
tion time (9.5±4.6 vs 16.6±6.4 hours, p< 0.001). A neurological event was recorded in 
3 sutureless patients and in 6 sutures (p= 0.248). Sutured has an higher incidence 
of postoperative atrial fibrillation, pleura effusions and respiratory insufficiency (p 
0.015, 0.024 and 0.016, respectively). Reduced risk of post operative complication 
resulted in a dramatic reduction of resources consumption in the sutureless group 
allowing a saving of 50% of the complication related resource use. ConClusions: 
Shorter procedural times resulting from sutureless aortic valve replacement are 
associated with better outcomes and lower costs. Sutureless valve may be consid-
ered as the first-line treatment for patients underwent aortic valve replacement 
with a bioprosthesis.
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objeCtives: To assess the annual average costs and quality adjusted life years 
(QALYs) of stroke services in the UK before and after the introduction of the National 
Stroke Strategy (period: 2006-2011). Methods: Data from the South London Stroke 
Register (SLSR) from 2006 to 2011 were used to populate a discrete event simulation 
(DES) model. Parameters, such as daily probability of survival and length of stay, 
included in the model were calculated by using Cox proportional hazard model and 
multivariate regression methods respectively. Barthel Index was used as proxy for 
measures of quality of life. Treatment costs were introduced in the model in order 
to calculate the total costs based on resource usage. The model simulated the stroke 
care delivery from stroke onset with 10-year follow up. Average cost and QALYs 
were calculated for every year from 2006 to 2011. Results: The average total costs 
per treating a stroke patient decreased from £30,745 to £27,086 between 2006 and 
2011 (p-value for trend < 0.001). This is mainly as a result of savings achieved in the 
inpatient phase due to a shorter LOS and a higher proportion of patients with mild 
disability. Per patient QALY’s also increased from 2.2 to 3.1 during the same period 
(p-value for trend < 0.001), this is due to a higher proportion of patients having 
access to better organised stroke care. ConClusions: This study has demonstrated 
that stroke services in the UK have improved their value for money over time with 
constant gains in efficiency. The use of DES together with SLSR data allows the test-
ing of the costs and outcomes of a whole stroke provision system or components 
of it and provide opportunities for retrospective (as done in this study) as well as 
prospective analysis (in the case of health technology assessment studies).
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objeCtives: To assess the impact of a hypothetical increase in the stroke primary 
preventive care coverage in the UK. Productivity gains, using resource utilization 
as proxy, and monetary benefits were calculated. Methods: Data from the South 
London Stroke Register (SLSR) from 2009 to 2011 were used to create a hypothetical 
cohort to populate a discrete event simulation (DES) model. The model simulated 
the stroke care delivery from primary preventive stroke care until discharge from 
stroke unit or general medical ward. Primary preventive care was defined as taking 
medications to control hypertension, high-cholesterol and also anticoagulants in 
patients with atrial fibrillation in order to prevent strokes. Treatment costs were 
introduced in the model in order to calculate the total costs based on resource usage. 
Hypothetical scenarios consisting in 10% incremental increase of primary preven-
tive care for high-risk factors were tested. The reduction of strokes was given by 
relative risk reduction ratios extracted from clinical trials. Results: Our findings 
indicate that for every 10% increase in the number of patients undergoing primary 
prevention treatment the number of strokes would be reduced by 1.2%. In a scenario 
where 50% of the untreated patients receive primary prevention 7,232 strokes would 
be reduced per year. For the same scenario, 47 hyper acute beds, 359 acute beds and 
47 general medical ward beds could be saved in average. In total this would yield in 
£42.2 million of savings in the inpatient phase of stroke care. ConClusions: Our 
findings suggest that by enhancing primary prevention of stroke care in the UK, 
significant benefits can be achieved in terms of reductions in resource consumption 
and monetary savings as a result of averted strokes. The generation and analysis 
of these retrospective hypothetical scenarios, using real-world evidence on stroke, 
help evaluate policy choices in stroke care in the UK.
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objeCtives: Greater than 40% of Europeans over age 25 have hypertension, and 10% 
of those have medication resistant hypertension (RHT). In EU5 (France, Germany, 
Italy, Spain, UK) that results in 9.4 million persons with blood pressure above goal, 
despite treatment with 3+ medications. These patients have a greater than 30% 
risk of cardiovascular disease (CVD) over 10 years and an increased risk of end-
stage renal disease (ESRD). This analysis sought to quantify the burden of RHT 
10 days since acute stroke onset, 2,000 mg was administered intravenously; from day 
11 to the end of the treatment periods (74 days), 1,000 mg was administered per os. 
The time horizon adopted in the model was 12 weeks. Based on the data on effective-
ness of citicoline in complete patient recovery after 3 months reported by A. Davalos 
et al., the cost-effectiveness ratios (CERs) were calculated and compared. Results: 
Estimated CERs were 513,099.20 RUB per one patient recovered in control group and 
435,368.00 RUB per one patient recovered in citicoline group. Furthermore, the costs 
of rehabilitation of patients were lower in the citicoline group as compared to control 
group, cost savings were estimated to be about 1,719,610.00 RUB. ConClusions: The 
study has demonstrated that the treatment of acute ischemic stroke with citicoline 
was more cost-effective and had the potential to reduce the rehabilitation expenses.
PCV48
remoTe PaTienT moniToring in CrT-d reCiPienTs may reduCe use of 
hosPiTal-Based Care
Stern S.1, Kansal A.R.1, Amorosi S.L.2, de Lissovoy G.3
1Evidera, Bethesda, MD, USA, 2Boston Scientific, Natick, MA, USA, 3Johns Hopkins University, 
Baltimore, MD, USA
objeCtives: Heart failure (HF) is a costly disease imposing a substantial health 
burden which affects 1-2% of Europeans. Hospital readmission for HF is a common 
occurrence with 25% of all patients readmitted within 30-days following initial 
hospitalization. Reducing readmission is an important component of managing HF 
costs and increasingly being targeted with health care policy reforms. The objec-
tive of this study is to examine how remote patient monitoring (RPM) may affect 
health care costs following the placement of a CRT-D device for patients with HF 
through the use of a simulation model. Methods: The analysis was an individual 
patient event-based simulation from a US payer perspective based on a sample 
of patients from RAPID-RF, a multi-center prospective single-arm registry which 
enrolled 889 patients who received a CRT-D and RPM system (LATITUDE® Boston 
Scientific). The modeled population consisted of patients that had at least one alert 
for weight change, atrial tachycardia or ICD shock with a subsequent interven-
tion (N= 128). The population was limited to this subset to focus on the costs of 
changes in management due to RPM. A non-RPM control group was created by 
cloning each trial patient and simulating their response in the absence of RPM to the 
conditions that triggered each alert in the trial over one year using a decision tree 
which computed rates of hospitalization and physician contacts based on literature 
data. Event and hospitalization costs were estimated per Medicare (CMS) national 
average payment. Results: RPM reduced total costs after the index procedure by 
$323/patient driven by a reduction in costs related to hospitalization admissions. 
The decrease in hospital admission cost was partially offset by RPM’s increase in 
physician visits and telephone counseling. ConClusions: RPM has the potential 
to shift HF-related care from an inpatient setting to office-based care, resulting in 
cost savings to national payers.
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objeCtives: Analysis of cost containment of SSI via use of Dabigatran Etexilate 
(150MG) versus current standard of care (Warfarin) in prevention of stroke for non 
valvular atrial fibrillation patients in Turkish health care setting. Methods: All 
calculations are performed for a group of 1000 patients in each treatment arm per 
year (Treatment arms; Dabigatran 150MG & Warfarin 5MG – results are represented 
as “cost per patient per day”). Available clinical data is analyzed for calculation of 
event costs in each treatment arm (RE-LY study). Local costs of events are included 
from local literature. Microsoft Excel (2007) is used for calculations and construc-
tion of data tables. Results: Direct cost of SSI (indirect costs are not included in 
this analysis) is calculated in each treatment arm. Difference of daily medication 
cost between Dabigatran Etexilate and Warfarin treatments is +3.12 TL/Day*Patient 
however, this difference is calculated as -3.34 TL/Day*Patient when medication 
cost is combined with total treatment cost (costs of thromboembolic&adverse 
events, INR monitoring, impairment). Dabigatran Etexilate offers a cost contain-
ment (saving) of 0.22 TL/Day*Patient in prevention of stroke for non valvular atrial 
fibrillation patients in Turkish health care setting. ConClusions: Limitation of 
this study is covering only direct cost data due to lack of local literature on indirect 
costs. Further analysis may be performed by non-interventional studies, which 
will define cost containment data via real life cost and effectiveness values. This 
study demonstrates that Dabigatran Etexilate treatment may sustain cost contain-
ment (saving) via reduction of direct cost of SSI with respect to current standard of 
care, in prevention of stroke in patients with atrial fibrillation in current Turkish 
health care system.
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objeCtives: New sutureless aortic valve prostheses reduce the surgical time. 
Objective of this study is to asses if shorter operative times may also result in 
improved patient outcomes and the impact on the hospital costs. Methods: 
Records of 547 patients that underwent aortic valve replacement with a biopros-
thesis from March 2009 and May 2013 were identified. Based on a propensity score 
analysis 2 groups (Sutureless and Sutured) with 82 matched pairs were created from 
the 112 patients received a Perceval sutureless bioprosthesis and the 435 patients 
received a sutured valve. Hospital and follow up outcomes, resources consumption 
was recorded and compared between groups. Analysis was performed according 
